Related Experiment Video

Updated: May 31, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

Impact of 'targeted' fluconazole prophylaxis for preterm neonates: efficacy of a highly selective approach?

A Martin1, A Pappas, M Lulic-Botica

  • 1Division of Neonatology, Department of Pediatrics, Wayne State University, Detroit, MI, USA.

Journal of Perinatology : Official Journal of the California Perinatal Association
|July 16, 2011
PubMed

Insights

Targeted intermittent fluconazole prophylaxis (FP) significantly reduced invasive candidiasis rates in high-risk preterm infants. This strategy proved effective in preventing serious fungal infections in vulnerable newborns.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive candidiasis is a serious complication in preterm infants, particularly those receiving broad-spectrum antibiotics.
  • Identifying effective prophylactic strategies is crucial for improving outcomes in high-risk neonatal populations.

Purpose of the Study:

  • To assess the efficacy of targeted intermittent fluconazole prophylaxis (FP) in reducing invasive candidiasis among high-risk preterm infants.
  • To evaluate the impact of this targeted approach on specific neonatal intensive care unit (NICU) morbidities.

Main Methods:

  • An observational pre-post cohort study involving 524 preterm infants (birth weight <1500g, <6 weeks old).
  • Targeted FP (3 mg/kg) was administered to infants receiving >2 days of broad-spectrum antibiotics with at least one additional risk factor for invasive candidiasis.
  • Data on invasive candidiasis rates and other morbidities were compared between periods with and without targeted FP.

Main Results:

  • Invasive candidiasis incidence decreased significantly from 15.3% to 6.2% during the FP period.
  • However, the FP period saw significantly longer durations of parenteral nutrition, central line use, and higher rates of necrotizing enterocolitis.
  • FP was given to 31.3% of eligible infants, with a median of 4 doses over 7 days.

Conclusions:

  • Targeted intermittent fluconazole prophylaxis is effective in reducing invasive candidiasis rates in a select group of high-risk preterm infants.
  • While effective for fungal infection prevention, careful monitoring for potential adverse effects on other neonatal morbidities is warranted.
Abstract

More Related Videos

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...